AKT inhibitor

DRUG2 trials

Sponsors

Fudan University, University of Miami

Conditions

Advanced Breast CancerBreast CancerBreast NeoplasmER-positive Breast CancerHER2-negative Breast CancerHormone Receptor Positive TumorMetastatic Breast Cancer

Phase 2

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

RecruitingNCT05594095

Fudan UniversityAdvanced Breast Cancer, Breast Cancer, Breast Neoplasm +2

Start: 2022-12-30End: 2026-12-01Target: 620Updated: 2024-10-04

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Active, not recruitingNCT05826964

University of MiamiBreast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer +1

Start: 2023-06-12End: 2029-07-31Target: 24Updated: 2026-01-13

Related Papers

Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.

2025-12-04

Abstract P2-09-17: Precision medicine based on similarity network fusion (SNF) subtypes of multi-omics in CDK4/6 inhibitor failed HR+/ HER2- advanced breast cancer: the Linux trial

Clinical Cancer Research2025-06-13